Claims for Patent: 6,833,380

Summary for Patent: 6,833,380

Title:	Compounds that modulate PPAR activity and methods of preparation
Abstract:	This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
Inventor(s):	Cheng; Xue-Min (Ann Arbor, MI), Erasga; Noe (Ann Arbor, MI), Filzen; Gary Frederick (Ann Arbor, MI), Geyer; Andrew (Novi, MI), Lee; Chitase (Ann Arbor, MI), Trivedi; Bharat Kalidas (Farmington Hills, MI)
Assignee:	Warner-Lambert Company, LLC (Morris Plains, NJ)
Application Number:	10/324,278
Patent Claims:	1. A compound having formula I: ##STR59## or a pharmaceutically acceptable salt thereof, wherein: T is a saturated or unsaturated, substituted or unsubstituted hydrocarbon chain or hydrocarbon-heteroatom chain having from 3 to 6 atoms wherein the carbon atom of position 2 is connected to the carbon atom of position 3 to form a five to eight member ring; W is O, S, CH.sub.2, CR.sup.4 R.sup.5, NR.sup.3, cycloalkylene, or heterocycloalkylene; Y is absent, O, or CR.sup.4 R.sup.5 wherein Y is CR.sup.4 R.sup.5 or absent when W is O, S, or NR.sup.3 ; and Y is O or absent when W is CH.sub.2 or CR.sup.4 R.sup.5 ; R.sup.1 and R.sup.2 are independently hydrogen, lower alkyl, lower alkoxy, haloalkyl, --O--(CH.sub.2).sub.p CF.sub.3, halogen, nitro, cyano, --OH, --SH, --CF.sub.3, --S(O).sub.p alkyl, S(O).sub.p aryl, --(CH.sub.2).sub.m OR.sup.3, --(CH.sub.2).sub.m NR.sup.6 R.sup.7, --COR.sup.3, --CO.sub.2 H, --CO.sub.2 R.sup.3, or --NR.sup.6 R.sup.7 ; R.sup.3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; R.sup.4 and R.sup.5 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, or joined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R.sup.6 and R.sup.7 are independently hydrogen, alkyl, alkenyl, alkynyl, --COalkyl, --COaryl, cycloalkyl, --CO.sub.2 alkyl, --CO.sub.2 aryl, --SO.sub.2 alkyl, --SO.sub.2 aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms; X.sup.0 and X.sup.1 are independently O or S; Ar.sup.1 is substituted or unsubstituted aryl or heteroaryl; m is 0 to 5; n is 0 to 5; and p is 0 to 2. 2. The compound of claim 1, wherein W is O, Y is absent, and n is 1. 3. The compound of claim 1, wherein T is substituted with 1 or more substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, --O(CH.sub.2).sub.0-2 CF.sub.3, halogen, nitro, cyano, .dbd.O, .dbd.S, --OH, --SH, --CF.sub.3, --OCF.sub.3, --CO.sub.2 H, --CO.sub.2 C.sub.1 -C.sub.6 alkyl, --NH.sub.2, --NHC.sub.1 -C.sub.6 alkyl, --OCH.sub.2 O--, and --N(C.sub.1 -C.sub.6 alkyl).sub.2. 4. The compound of claim 1, wherein: T is --CH.sub.2 CH.sub.2 CO--O--, --CH.sub.2 --CH.sub.2 --O--CO--, --CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 --, --HC.dbd.CH--HC.dbd.CH--, --N.dbd.CH--HC.dbd.CH--, --HC.dbd.N--HC.dbd.CH--, --HC.dbd.CH--N.dbd.CH--, --HC.dbd.CH--HC.dbd.N--, --CH.sub.2 --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --O--CH.sub.2 --, --CH.sub.2 --HC.dbd.CH--CH.sub.2 --, --CH.sub.2 --HC.dbd.CH--, --CH.sub.2 CH.sub.2 --NH--CH.sub.2 --, --COCH.dbd.CH--O--, --O--CH.dbd.CH--CO--, --CH.dbd.CH--NR.sup.4 --, --NR.sup.4 --CH.dbd.CH--, --CH.dbd.CH--CH.sub.2 --, --CH.sub.2 --CH.sub.2 --NR.sup.4 --, --NR.sup.4 --CH.sub.2 --CH.sub.2 --, --O--CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --O--, --CH.sub.2 --CH.sub.2- CO--, --CH.sub.2 --CO--CH.sub.2-, --CO--CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CH.sub.2 --CO--, --CO--CH.sub.2 --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CO--CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CO--CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CH.sub.2 --NR.sup.4 --, --NR.sup.4 --CH.sub.2 --CH.sub.2 --CH.sub.2 --, --O--CH.sub.2 --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CH.sub.2 --O--, --CO--NR.sup.4 --CH.sub.2 --CH.sub.2 --, NR.sup.4 CO--CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CH.sub.2-- NR.sup.4 --CO--, or --CH.sub.2 --CH.sub.2 --CO--NR.sup.4 --. 5. The compound of claim 1, wherein: R.sup.1 and R.sup.2 are independently hydrogen, alkyl, or alkoxy. 6. The compound of claim 1, wherein: R.sup.1 is hydrogen; and R.sup.2 is alkyl or alkoxy. 7. The compound of claim 1, wherein: R.sup.1 is hydrogen; and R.sup.2 is alkoxy. 8. The compound of claim 1, wherein: R.sup.1 is hydrogen, methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl; and R.sup.2 is methyoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, or isobutoxy. 9. A compound having Formula IIa, Formula IIb, Formula IIc, Formula IId, or Formula IIe: ##STR60## ##STR61## or a pharmaceutically acceptable salt thereof, wherein: Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are independently a carbon atom or a heteroatom wherein the carbon atom and the heteroatom are bonded to a sufficient number of hydrogen atoms or substituents to complete the valency of each atom with the proviso that Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are not all heteroatoms and that not more than two adjacent atoms in Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are heteroatoms and that in Formulae IIb, IIc, and IId, Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are not all carbon; W is O, S, CH.sub.2, CR.sup.4 R.sup.5, NR.sup.3, cycloalkylene, or heterocycloalkylene; Y is absent, O, or CR.sup.4 R.sup.5 wherein Y is CR.sup.4 R.sup.5 or absent when W is O, S, or NR.sup.3 ; and Y is O or absent when W is CH.sub.2 or CR.sup.4 R.sup.5 ; R.sup.1 and R.sup.2 are independently hydrogen, lower alkyl, lower alkoxy, haloalkyl, --O--(CH.sub.2).sub.p CF.sub.3, halogen, nitro, cyano, --OH, --SH, --CF.sub.3, --S(O).sub.p alkyl, S(O).sub.p aryl, --(CH.sub.2).sub.m OR.sup.3, --(CH.sub.2).sub.m NR.sup.6 R.sup.7, --COR.sup.3, --CO.sub.2 H, --CO.sub.2 R.sup.3, or --NR.sup.6 R.sup.7 ; R.sup.3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; R.sup.4 and R.sup.5 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, or joined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R.sup.6 and R.sup.7 are independently hydrogen, alkyl, alkenyl, alkynyl, --COalkyl, --COaryl, cycloalkyl, --CO.sub.2 alkyl, --CO.sub.2 aryl, --SO.sub.2 alkyl, --SO.sub.2 aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms; X.sup.0 and X.sup.1 are independently O or S; Ar.sup.1 is substituted or unsubstituted aryl or heteroaryl; m is 0 to 5; n is 0 to 5; and p is 0 to 2. 10. The compound of claim 9, wherein W is O, Y is absent, and n is 1. 11. The compound of claim 9, wherein the heteroatom is N, O, or S. 12. The compound of claim 9, wherein: R.sup.1 and R.sup.2 are independently hydrogen, alkyl, or alkoxy. 13. The compound of claim 9, wherein: R.sup.1 is hydrogen; and R.sup.2 is alkyl or alkoxy. 14. The compound of claim 9, wherein: R.sup.1 is hydrogen; and R.sup.2 is alkoxy. 15. The compound of claim 9, wherein: R.sup.1 is hydrogen, methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl; and R.sup.2 is methyoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, or isobutoxy. 16. A compound having Formula IIIa, Formula IIIb, or Formula IIIc: ##STR62## or a pharmaceutically acceptable salt thereof, wherein: W is O, S, CH.sub.2, CR.sup.4 R.sup.5, NR.sup.3, cycloalkylene, or heterocycloalkylene; Y is absent, O, or CR.sup.4 R.sup.5 wherein Y is CR.sup.4 R.sup.5 or absent when W is O, S, or NR.sup.3 ; and Y is O or absent when W is CH.sub.2 or CR.sup.4 R.sup.5 ; R.sup.1 and R.sup.2 are independently hydrogen, lower alkyl, lower alkoxy, haloalkyl, --O--(CH.sub.2).sub.p CF.sub.3, halogen, nitro, cyano, --OH, --SH, --CF.sub.3, --S(O).sub.p alkyl, S(O).sub.p aryl, --(CH.sub.2).sub.m OR.sup.3, --(CH.sub.2).sub.m NR.sup.6 R.sup.7, --COR.sup.3, --CO.sub.2 H, --CO.sub.2 R.sup.3, or --NR.sup.6 R.sup.7 ; R.sup.3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; R.sup.4 and R.sup.5 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, or joined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R.sup.6 and R.sup.7 are independently hydrogen, alkyl, alkenyl, alkynyl, --COalkyl, --COaryl, cycloalkyl, --CO.sub.2 alkyl, --CO.sub.2 aryl, --SO.sub.2 alkyl, --SO.sub.2 aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms; X.sup.0 and X.sup.1 are independently O or S; Ar.sup.1 is substituted or unsubstituted aryl or heteroaryl; m is 0 to 5; n is 0 to 5; p is 0 to 2; and Z.sup.1, Z.sup.2, and Z.sup.3 are independently a carbon atom or a heteroatom wherein the carbon atom and the heteroatom are bonded to a sufficient number of hydrogen atoms or substituents to complete the valency of each atom with the proviso that Z.sup.1, Z.sup.2, and Z.sup.3 are not all heteroatoms and that in Formulae IIIa and IIIb Z.sup.1, Z.sup.2, and Z.sup.3 are not all carbon atoms. 17. The compound of claim 16, wherein W is O, Y is absent, and n is 1. 18. The compound of claim 16, wherein: R.sup.1 and R.sup.2 are independently hydrogen, alkyl, or alkoxy. 19. The compound of claim 16, wherein: R.sup.1 is hydrogen; and R.sup.2 is alkyl or alkoxy. 20. The compound of claim 16, wherein: R.sup.1 is hydrogen; and R.sup.2 is alkoxy. 21. The compound of claim 16, wherein: R.sup.1 is hydrogen, methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl; and R.sup.2 is methyoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, or isobutoxy. 22. A compound selected from {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-5-oxo -5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-8-oxo -5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-7-oxo -5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-6-oxo -5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-4-oxo -4H-chromen-8-yloxy}-acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-4-oxo -4H-chromen-5-yloxy}-acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-4-oxo -chroman-5-yloxy}-acetic acid; {5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-4-oxo -chroman-8-yloxy}-acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-quino lin-5-yloxy}-acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-isoqu inolin-5-yloxy}-acetic acid; {1-Methyl-7-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfan yl]-1H-benzoimidazol-4-yloxy}-acetic acid; {3-Methyl-7-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfan yl]-1H-benzoimidazol-4-yloxy}-acetic acid; {7-[4-Methyl-2-(4-triluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-1H-ind ol-4-yloxy}-acetic acid; {1-Methyl-7-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfan yl]-1H-indol-4-yloxy}-acetic acid; {7-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-benzo [b]thiophen-4-yloxy}-acetic acid; {7-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-benzo furan-4-yloxy}-acetic acid; {8-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-chrom an-5-yloxy}-acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-5,6,7 ,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-napht halen-1-yloxy}-acetic acid; 2-[6-methyl-8-({4-methyl-2-[4-(trifluoromethyl)phenyl](1,3-thiazol-5-yl)}me thylthio)chroman-5-yloxy]acetic acid; 2-[5-methyl-7-({4-methyl-2-[4-(trifluoromethyl)phenyl](1,3-thiazol-5-yl)}me thylthio)-2,3-dihydrobenzo[b]furan-4-yloxy]acetic acid; {5-Methyl-7-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfan yl]-indan-4-yloxy}-acetic acid; {7-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-indan -4-yloxy}-acetic acid; and pharmaceutically acceptable salts thereof. 23. A pharmaceutical composition comprising a compound of claim 1 and one or more pharmaceutically acceptable carriers, diluents, or excipients. 24. A method of treating or controlling obesity in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1. 25. A method of treating or controlling hyperlipidemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1. 26. A method of treating or controlling hypercholesteremia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1. 27. A method of treating or controlling atherosclerosis in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1. 28. A method of treating or controlling hypertriglyceridemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1. 29. A method of treating a patient exhibiting glucose disorders associated with circulating glucocorticoids, growth hormone, catecholamines, glucagon, or parathyroid hormone, comprising administering to the patient a therapeutically effective amount of a compound of claim 1. 30. A method of making the compound of claim 1, the method comprising, reacting: ##STR63## wherein X is a halogen; X.sup.0 and X.sup.1 are independently O or S; Ar.sup.1 is substituted or unsubstituted aryl or heteroaryl; T is a saturated or unsaturated, substituted or unsubstituted hydrocarbon chain or hydrocarbon-heteroatom chain having from 3 to 6 atoms wherein the carbon atom of position 2 is connected to the carbon atom of position 3 to form a five to eight member ring; W is O, S, CH.sub.2, CR.sup.4 R.sup.5, NR.sup.3, cycloalkylene, or heterocycloalkylene; Y is absent, O, or CR.sup.4 R.sup.5 wherein Y is CR.sup.4 R.sup.5 or absent when W is O, S, or NR.sup.3 ; and Y is O or absent when W is CH.sub.2 or CR.sup.4 R.sup.5 ; R.sup.1 and R.sup.2 are independently hydrogen, lower alkyl, lower alkoxy, lower thioalkoxy, --O(CH.sub.2).sub.p CF.sub.3, halogen, nitro, cyano, --OH, --SH, --CF.sub.3, --OCF.sub.3, S(O).sub.n Alkyl, S(O).sub.p Aryl, --(CH.sub.2).sub.m OR.sup.3, --(CH.sub.2).sub.m NR.sup.6 R.sup.7, COR.sup.3, --CO.sub.2 H, --CO.sub.2 R.sup.3, or --NR.sup.6 R.sup.7 ; R.sup.3 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; R.sup.4 and R.sup.5 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, or joined together to form a 4 to 7 member ring having 0 to 3 heteroatoms; R.sup.6 and R.sup.7 are independently hydrogen, alkyl, alkenyl, alkynyl, --COalkyl, --COaryl, cycloalkyl, --CO.sub.2 alkyl, --CO.sub.2 aryl, --SO.sub.2 alkyl, --SO.sub.2 aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms; m is 0 to 5; n is 0 to 5; and p is 0 to 2.

Details for Patent 6,833,380

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2022-03-07